Journal of Clinical Oncology · 2001 · 140 citations · 22 references
MedicineHematologyMolecular BiologyCytogeneticsHematologic OncologyHematopathologyHematologic MalignanciesHematologic PathologyImmunoglobulin Gene RearrangementLymphoid NeoplasmsLymphoid TumorsMinimal Residual DiseaseImmunoglobulin Heavy Chain RearrangementImmunoglobulin Light Chain RearrangementMinimal Residual Disease MarkersMinimal Residual Disease StratificationMolecular Residual Disease MonitoringPeripheral Blood Lymphocyte AnalysisRearrangement FrequencyTumor Burden Measurement
PURPOSE: To determine the incidence and frequency of the Bcl-2/IgH rearrangement in the peripheral blood of normal individuals to define the potential complication this may pose for the molecular monitoring of disease in patients with follicular lymphoma (FL). MATERIALS AND METHODS: The incidence and frequency of the major breakpoint cluster region rearrangement in DNA extracted from peripheral blood or lymphoblastoid cell lines from 481 normal individuals was determined using a TaqMan real-time polymerase chain reaction assay (PE Applied Biosystems, Foster City, CA). RESULTS: Twenty three percent of samples were positive for the Bcl-2/IgH rearrangement, with approximately 3% of these at levels of more than 1 in 10(4) cells. CONCLUSION: The presence of circulating Bcl-2/IgH+ cells, other than those derived from the malignant clone, could confound the detection and quantitation of minimal residual disease in patients with FL, particularly at low levels of tumor burden.
22
Michael L. Cleary, Jeffrey Sklar · Proceedings of the National Academy of Sciences · 1985 · 954 citations
Follicular lymphoma: prognostic factors for response and survival.
C. Gallagher, Walter M. Gregory, A. E. Jones et al. · Journal of Clinical Oncology · 1986 · 431 citations
Medicine, Hematology, Oncology +17
Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals
Jacqueline Limpens, Robert Stad, Catharina M.P. Vos et al. · Blood · 1995 · 415 citations · Full text
Medicine, Hematology, Oncology +12